ClinicalTrials.gg
CompletedNCT03605680Updated Mar 15, 2022Results posted

A Trial Evaluating the Efficacy, Safety, & Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder

A Phase 3 interventional study of Centanafadine SR and Placebo in Attention Deficit Disorder and Attention Deficit Hyperactivity Disorder, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2022-03-15.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
604
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing centanafadine in Attention Deficit Disorder with Hyperactivity — 5 open to participants now, 5 under way, 5 of them phase 3. centanafadine · Attention Deficit Disorder with Hyperactivity.

Enrollment
4th of 20
604 · median 180
Started
2019
with 3 others
Phase 3
10 of 20
3 open now
Registered
3rd of 20
by date
Lead sponsor
16 of 20
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 20 studies testing centanafadine in Attention Deficit Disorder with Hyperactivity, this one is the 4th largest by enrollment, is one of 4 that started in 2019, is one of 10 in phase 3, and was the 3rd registered.

Attention Deficit Disorder with Hyperactivity

1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.

Browse Attention Deficit Disorder with Hyperactivity studies →

Open to participants now

5 of the 20 studies testing centanafadine in Attention Deficit Disorder with Hyperactivity are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About centanafadine

centanafadine: first FDA approval 2026 (SIMTRIYO). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing centanafadine in Attention Deficit Disorder with Hyperactivity, or all of them as a file.
02

Study summary

This study evaluates the efficacy, safety, and tolerability of centanafadine sustained-release tablets in adults with attention-deficit/hyperactivity disorder (ADHD). Participants will either receive a twice-daily dose of centanafadine sustained-release tablets, or twice-daily placebo.

Read the detailed description

Screening \& Washout Period: up to 28 days Investigational Treatment Period: 49 days Follow-up Period : 7 days or 10 days

03

Conditions studied

  • Attention Deficit Disorder
  • Attention Deficit Hyperactivity Disorder

Keywords

  • Centanafadine
  • ADHD
  • ADD
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must meet the Fifth Edition (DSM-5) criteria for ADHD (including predominantly inattentive presentation, hyperactive presentation, or combined presentation) as confirmed by the Adult ADHD Clinical Diagnostic Scale (ACDS) Version 1.2. To confirm that ADHD is the primary diagnosis, the Mini International Neuropsychiatric Interview (MINI) will be used to identify and exclude other psychiatric conditions which would preclude enrollment.
  • Participants who were not receiving any pharmacological treatment for ADHD must have an Adult ADHD Investigator Symptom Rating Scale (AISRS) score of ≥ 28 at screening and baseline. Participants who were receiving pharmacological treatment for ADHD at screening must have a minimum AISRS score of ≥ 22 at screening, and a score of ≥ 28 at baseline.
  • All participants must be willing to discontinue all prohibited psychotropic medications starting from the time of signing the through the 7-day follow-up period. Participants that do not rollover into Trial 405-201-00015 (NCT03605849) must be willing to discontinue all prohibited psychotropic medications starting from the time of signing the informed consent until after the follow-up telephone call 10 days after the last dose of medicinal product (IMP).
  • Participants must have a Clinical Global Impression-Severity of Illness Scale (CGI-S) score of ≥ 4 (≥ moderate impairment) at baseline.

Exclusion criteria

Exclusion Criteria:

  • Participants with a diagnosis of Other Specified or Unspecified Attention Deficit/Hyperactivity Disorder.
  • Participants has a current comorbid psychiatric disorder that either could be expected to require treatment with medications prohibited in this trial, or to confound efficacy or safety assessments. Examples include, but are not limited to, psychotic disorder, bipolar disorder, generalized anxiety disorder, obsessive-compulsive disorder, panic disorder, a current major depressive episode, or posttraumatic stress disorder, as established by the Mini International Neuropsychiatric Interview (MINI).
  • In the opinion of the investigator, participants has not derived significant therapeutic benefit from 2 or more ADHD therapies of 2 different classes (eg, amphetamine and methylphenidate) given with an acceptable dose and duration during adulthood (aged 18 or older). NOTE: If participants has not derived significant therapeutic benefit due to an inability to tolerate side effects, eligibility can be discussed on case-by-case basis with the medical monitor.
  • Participants who have a positive alcohol test (via breathalyzer or blood), a positive drug screen assessed prior to the baseline visit for cocaine, other illicit drugs (including marijuana), or prescription or over-the-counter (OTC) ADHD medications will be early terminated. This includes medications such as opioids or benzodiazepines taken without prescription.
  • In the opinion of the investigator, the participants is unable to adhere to the treatment regimen or other requirements outlined in the protocol.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
604 participants (actual)

Study arms

  • Experimental
    Single-blind Run-in Period: Placebo

    Placebo-matching tablets BID (twice daily) on Day -7 through Baseline (Day -1).

    Other: Placebo

  • Experimental
    Double-blind Treatment Period: Centanafadine SR 200 mg

    Following Single-blind Run-in Period, participants with \<30% improvement on Adult ADHD Self Report Scale (ASRS) scale score were randomized to receive centanafadine 200 mg SR tablets BID orally on Day 1 through Day 42 in the Double-blind Treatment Period.

    Drug: Centanafadine SR

  • Experimental
    Double-blind Treatment Period: Centanafadine SR 400 mg

    Following Single-blind Run-in Period, participants with \<30% improvement on Adult ADHD Self Report Scale (ASRS) scale score were randomized to receive centanafadine 400 mg SR tablets BID orally on Day 1 through Day 42 in the Double-blind Treatment Period.

    Drug: Centanafadine SR

  • Placebo comparator
    Double-blind Treatment Period: Placebo

    Following Single-blind Run-in Period, participants with \<30% improvement on Adult ADHD Self Report Scale (ASRS) scale score were randomized to receive centanafadine SR matching placebo tablets BID orally on Day 1 through Day 42 in the Double-blind Treatment Period.

    Other: Placebo

Interventions

  • 100 mg, BID, oral tablets

    Also known as: EB-1020

  • OtherPlacebo

    BID, oral tablet.

  • 200 mg, BID, oral tablets

    Also known as: EB-1020

06

What researchers measure

Primary outcomes

  1. Change From Baseline in ADHD Investigator Symptom Rating Scale (AISRS)

    The Adult Investigator Symptom Rating Scale (AISRS) is an 18-item clinician rating scale to evaluate individual ADHD symptoms on a scale of 0 (none) to 3 (severe). The total sum ranges from 0 (no ADHD symptoms) to 54 (extremely severe ADHD symptoms). Negative change from Baseline indicates improvement. Mixed-effect model repeated measure (MMRM) was used for analysis.

    Time frame: Baseline and Day 42

Secondary outcomes

  1. Change From Baseline in Clinical Global Impression-Severity of Illness Scale (CGI-S)

    CGI-S is an observer-rated scale used to measure symptom severity with a total score range of 0 to 7 where 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants. A negative change from Baseline indicates improvement. MMRM was used for the analysis.

    Time frame: Baseline and Day 42

Other outcomes

  1. Adverse Event Reporting

    Frequency and severity of treatment-emergent adverse events (TEAEs) will be assessed to determine safety and tolerability of centanafadine SR tablets.

    Time frame: Up to 59 days

  2. ADHD Impact Module - Adult (AIM-A)

    Scale composed of 3 subscales with a maximum score of 100. A lower score indicates a worse outcome. Exploratory endpoint; comparison of baseline score to other points throughout the study.

    Time frame: Up to 42 days

  3. Adult ADHD Self Report Scale (ASRS)

    An 18 question report, total score ranges from 0 to 124. A higher score denotes a worse outcome. Exploratory endpoint; comparison of baseline score to other points throughout the study.

    Time frame: Up to 42 days

  4. Adult ADHD Investigator Symptom Rating Scale (AISRS)

    Change from baseline total score compared to every scheduled visit. Each subscale is composed of 9 items each. Scores can range from 0 to 27, with a higher score representing a worse outcome. Change from baseline scores are compared to every scheduled visit score.

    Time frame: Up to 42 days

07

Results

Posted May 5, 2021

Participant flow

Participants took part in the study at 45 investigative sites in the United States from 16 January 2019 to 11 April 2020.

SB Placebo Run-in Period (1 Week)
Participant flow — SB Placebo Run-in Period (1 Week)
MilestoneSingle-blind (SB) Run-in Period: PlaceboDouble-blind Treatment Period: Centanafadine SR 200 mgDouble-blind Treatment Period: Centanafadine SR 400 mgDouble-blind Treatment Period: Placebo
Started604000
Treated584000
Completed466000
Not completed138000
Withdrew: Adverse event6000
Withdrew: Lack of efficacy1000
Withdrew: Lost to follow-up9000
Withdrew: Non-compliance with study drug3000
Withdrew: Protocol deviation13000
Withdrew: Withdrawal by subject12000
Withdrew: Site terminated by sponsor1000
Withdrew: Physician decision6000
Withdrew: Reason not specified87000
Double-blind Treatment Period (6 Weeks)
Participant flow — Double-blind Treatment Period (6 Weeks)
MilestoneSingle-blind (SB) Run-in Period: PlaceboDouble-blind Treatment Period: Centanafadine SR 200 mgDouble-blind Treatment Period: Centanafadine SR 400 mgDouble-blind Treatment Period: Placebo
Started0154156156
Completed0110117121
Not completed0443935
Withdrew: Randomized but not treated in double-blind treatment period0578
Withdrew: Adverse event0883
Withdrew: Lack of efficacy0001
Withdrew: Lost to follow-up0343
Withdrew: Non-compliance with study drug0312
Withdrew: Protocol deviation01475
Withdrew: Withdrawal by subject0447
Withdrew: Physician decision0120
Withdrew: Reason not specified0543
Withdrew: Reason due to covid-190123

Outcome measures

PrimaryChange From Baseline in ADHD Investigator Symptom Rating Scale (AISRS)

The Adult Investigator Symptom Rating Scale (AISRS) is an 18-item clinician rating scale to evaluate individual ADHD symptoms on a scale of 0 (none) to 3 (severe). The total sum ranges from 0 (no ADHD symptoms) to 54 (extremely severe ADHD symptoms). Negative change from Baseline indicates improvement. Mixed-effect model repeated measure (MMRM) was used for analysis.

Time frame:
Baseline and Day 42
Reported as:
Least squares mean · score on a scale
Change From Baseline in ADHD Investigator Symptom Rating Scale (AISRS)
score on a scaleDouble-blind Treatment Period: Centanafadine SR 200 mgDouble-blind Treatment Period: Centanafadine SR 400 mgDouble-blind Treatment Period: Placebo
Change From Baseline in ADHD Investigator Symptom Rating Scale (AISRS)-10.1 ± 0.99-9.73 ± 0.98-6.98 ± 0.98
Statistical analysis
  • Double-blind Treatment Period: Centanafadine SR 200 mg vs Double-blind Treatment Period: Placebo · MMRM · p = =0.0193 · Least squares (ls ) mean difference: -3.15 · 95% CI -5.79 to -0.51
  • Double-blind Treatment Period: Centanafadine SR 400 mg vs Double-blind Treatment Period: Placebo · MMRM · p = =0.0392 · Ls mean difference: -2.74 · 95% CI -5.35 to -0.14
SecondaryChange From Baseline in Clinical Global Impression-Severity of Illness Scale (CGI-S)

CGI-S is an observer-rated scale used to measure symptom severity with a total score range of 0 to 7 where 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants. A negative change from Baseline indicates improvement. MMRM was used for the analysis.

Time frame:
Baseline and Day 42
Reported as:
Least squares mean · score on a scale
Change From Baseline in Clinical Global Impression-Severity of Illness Scale (CGI-S)
score on a scaleDouble-blind Treatment Period: Centanafadine SR 200 mgDouble-blind Treatment Period: Centanafadine SR 400 mgDouble-blind Treatment Period: Placebo
Change From Baseline in Clinical Global Impression-Severity of Illness Scale (CGI-S)-0.78 ± 0.09-0.79 ± 0.08-0.52 ± 0.08
Statistical analysis
  • Double-blind Treatment Period: Centanafadine SR 200 mg vs Double-blind Treatment Period: Placebo · MMRM · p = =0.0232 · Ls mean difference: -0.27 · 95% CI -0.50 to -0.04
  • Double-blind Treatment Period: Centanafadine SR 400 mg vs Double-blind Treatment Period: Placebo · MMRM · p = =0.0162 · Ls mean difference: -0.28 · 95% CI -0.51 to -0.05
Other pre-specifiedAdverse Event Reporting

Frequency and severity of treatment-emergent adverse events (TEAEs) will be assessed to determine safety and tolerability of centanafadine SR tablets.

Time frame:
Up to 59 days

Results for this outcome have not been posted.

Other pre-specifiedADHD Impact Module - Adult (AIM-A)

Scale composed of 3 subscales with a maximum score of 100. A lower score indicates a worse outcome. Exploratory endpoint; comparison of baseline score to other points throughout the study.

Time frame:
Up to 42 days

Results for this outcome have not been posted.

Other pre-specifiedAdult ADHD Self Report Scale (ASRS)

An 18 question report, total score ranges from 0 to 124. A higher score denotes a worse outcome. Exploratory endpoint; comparison of baseline score to other points throughout the study.

Time frame:
Up to 42 days

Results for this outcome have not been posted.

Other pre-specifiedAdult ADHD Investigator Symptom Rating Scale (AISRS)

Change from baseline total score compared to every scheduled visit. Each subscale is composed of 9 items each. Scores can range from 0 to 27, with a higher score representing a worse outcome. Change from baseline scores are compared to every scheduled visit score.

Time frame:
Up to 42 days

Results for this outcome have not been posted.

Adverse events

Collected over Up to 59 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo: SB Run-in Period Only0/138 (0%)0/138 (0%)2/138 (1.4%)
Placebo + Centanafadine SR 200 mg0/149 (0%)2/149 (1.3%)25/149 (16.8%)
Placebo + Centanafadine SR 400 mg0/149 (0%)0/149 (0%)22/149 (14.8%)
Placebo + Placebo0/148 (0%)0/148 (0%)18/148 (12.2%)
Most frequent serious events
Most frequent serious events
EventPlacebo: SB Run-in Period OnlyPlacebo + Centanafadine SR 200 mgPlacebo + Centanafadine SR 400 mgPlacebo + Placebo
Gastroenteritis viralInfections and infestations0/1381/1490/1490/148
InfluenzaInfections and infestations0/1381/1490/1490/148
PneumoniaInfections and infestations0/1381/1490/1490/148
Most frequent other events
Most frequent other events
EventPlacebo: SB Run-in Period OnlyPlacebo + Centanafadine SR 200 mgPlacebo + Centanafadine SR 400 mgPlacebo + Placebo
HeadacheNervous system disorders2/1385/1497/14914/148
Decreased appetiteMetabolism and nutrition disorders0/1389/14911/1492/148
Dry MouthGastrointestinal disorders0/1386/1499/1490/148
Upper respiratory tract infectionInfections and infestations0/1388/1491/1493/148

Baseline characteristics

Participants who participated only in the Run-in Period and Full Analysis Set (FAS) including all participants in the safety sample who had a Baseline value and at least one valid post-randomization efficacy evaluation for adult ADHD investigator symptom rating scale (AISRS) total score in the Double-blind Treatment Period.

Age, Continuous
Age, Continuous(years)Placebo: Single-blind Run-in Period OnlyDouble-blind Treatment Period: Placebo + Centanafadine SR 200 mgDouble-blind Treatment Period: Placebo + Centanafadine SR 400 mgDouble-blind Treatment Period: Placebo + PlaceboTotal
Mean33.1 ± 9.436.6 ± 9.835.3 ± 10.435.0 ± 9.935.0 ± 9.9
Sex: Female, Male
Sex: Female, Male(Participants)Placebo: Single-blind Run-in Period OnlyDouble-blind Treatment Period: Placebo + Centanafadine SR 200 mgDouble-blind Treatment Period: Placebo + Centanafadine SR 400 mgDouble-blind Treatment Period: Placebo + PlaceboTotal
Female57767576284
Male81788180320
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo: Single-blind Run-in Period OnlyDouble-blind Treatment Period: Placebo + Centanafadine SR 200 mgDouble-blind Treatment Period: Placebo + Centanafadine SR 400 mgDouble-blind Treatment Period: Placebo + PlaceboTotal
Hispanic or Latino28343829129
Not Hispanic or Latino110119116124469
Unknown or Not Reported01236
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo: Single-blind Run-in Period OnlyDouble-blind Treatment Period: Placebo + Centanafadine SR 200 mgDouble-blind Treatment Period: Placebo + Centanafadine SR 400 mgDouble-blind Treatment Period: Placebo + PlaceboTotal
American Indian or Alaska Native10304
Asian542415
Native Hawaiian or Other Pacific Islander11103
Black or African American2219232185
White107126123130486
More than one race00000
Unknown or Not Reported244111
Adult Attention-deficit/Hyperactivity Disorder (ADHD) Investigator Symptom Rating Scale (AISRS)
Adult Attention-deficit/Hyperactivity Disorder (ADHD) Investigator Symptom Rating Scale (AISRS)(score on a scale)Placebo: Single-blind Run-in Period OnlyDouble-blind Treatment Period: Placebo + Centanafadine SR 200 mgDouble-blind Treatment Period: Placebo + Centanafadine SR 400 mgDouble-blind Treatment Period: Placebo + PlaceboTotal
Mean—39.7 ± 6.739.4 ± 6.839.4 ± 7.139.5 ± 6.8
Clinical Global Impression-Severity of Illness Scale (CGI-S)
Clinical Global Impression-Severity of Illness Scale (CGI-S)(score on a scale)Placebo: Single-blind Run-in Period OnlyDouble-blind Treatment Period: Placebo + Centanafadine SR 200 mgDouble-blind Treatment Period: Placebo + Centanafadine SR 400 mgDouble-blind Treatment Period: Placebo + PlaceboTotal
Mean—4.5 ± 0.64.5 ± 0.64.5 ± 0.64.5 ± 0.6
08

Study locations

1 site
  • For additional information regarding sites, contact 844-687-8522
    New York, New York 10022, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.

Access criteria: Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/

Data sharing details ↗ · clinical-trials.otsuka.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2019 to primary completion in Apr 2020, 14 months.

Results were first posted in May 2021, 1 year after primary completion.

Of 66 industry-sponsored phase 3 interventional studies under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 19. This study's 14 months is above that.

Counting every sponsor, half of 80 studies reached it within 14 months; a quarter within 7 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2018
First posted
Jul 30, 2018
StartActual
Jan 16, 2019
Primary completionActual
Apr 11, 2020
CompletionActual
Apr 11, 2020
Results first posted
May 5, 2021
Last update
Mar 15, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 15, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03605680
Responsible party
Sponsor
First posted
Jul 30, 2018
Start date
Jan 16, 2019
Primary completion
Apr 11, 2020
Completion
Apr 11, 2020
Results posted
May 5, 2021
Last update
Mar 15, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Centanafadine

Start the discussion